@article{oai:tsukuba.repo.nii.ac.jp:00049327,
 author = {秋山, 梓 and AKIYAMA, Azusa and 櫻井, 学 and SAKURAI, Manabu and 水口, 剛雄 and MINAGUCHI, Takeo and 沖, 明典 and OKI, Akinori and 佐藤, 豊実 and SATOH, Toyomi and 吉川, 裕之 and Onuki, Mamiko and Matsumoto, Koji and Tenjimbayashi, Yuri and Tasaka, Nobutaka and Yoshikawa, Hiroyuki},
 journal = {Papillomavirus Research},
 month = {Dec},
 note = {The prognostic impact of human papillomavirus (HPV) type on invasive cervical cancer (ICC) was analyzed for 137 women treated for ICC at a single institution between 1999 and 2007. The study subjects were divided into three groups according to HPV genotype: HPV16-positive (n = 59), HPV18-positive (n = 33), and HPV16/18-negative ICC (non-HPV16/18, n = 45). The median follow-up time was 102.5 months (range, 5–179). The 10-year overall survival (10y-OS) rates in women with FIGO stage I/II disease were similar among HPV genotypes: 94.7% for HPV16 (n = 39), 95.2% for HPV18 (n = 26), and 96.4% for non-HPV16/18 (n = 29). However, the 10y-OS rates in women with FIGO stage III/IV tumors were 73.7% for HPV16 (n = 20), 45.7% for HPV18 (n = 7), and 35.7% for other types (n = 16), with significantly higher survival in HPV16-positive compared with HPV16-negative ICC (10y-OS; 73.7% vs. 39.5%, P = 0.04). This difference in FIGO stage III/IV tumors remained significant after adjusting for age and histology (hazard ratio 0.30, 95% confidence interval 0.09–0.86, P = 0.02). These results suggest that detection of HPV16 DNA may be associated with a favorable prognosis in patients with FIGO stage III/IV ICC. Given that most women with FIGO stage III/IV tumors received concurrent chemoradiotherapy, this finding may imply that HPV16-positive tumors are more chemoradiosensitive.},
 pages = {41--45},
 title = {Human papillomavirus genotype and prognosis of cervical cancer: Favorable survival of patients with HPV16-positive tumors},
 volume = {6},
 year = {2018},
 yomi = {アキヤマ, アズサ and サクライ, マナブ and ミナグチ, タケオ and オキ, アキノリ and サトウ, トヨミ}
}